Thyroid disease, Diabetes
Conditions
Interventions
Group with hyperthyroidism and normal hepatic function:After an overnight fast of 8 to 10 hours, a 75g oral glucose tolerance test (OGTT), insulin and C-peptide release test, and glycated hemoglobin m
Group with hyperthyroidism and hepatic dysfunction:After an overnight fast of 8 to 10 hours, a 75g oral glucose tolerance test (OGTT), insulin and C-peptide release test, and glycated hemoglobin measu
Group with hyperthyroidism and antithyroid dr
Sponsors
The First Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Newly diagnosed Graves' disease hyperthyroidism patients, aged 18 to 70, regardless of gender. (2) Graves' disease without liver injury group: No elevation in AST, ALT, GGT, T-Bil, and D-Bil levels before and during treatment. Graves' disease-related liver injury group: Elevation in AST and/or ALT and/or GGT and/or T-Bil and/or D-Bil levels without medication treatment. ATD-related liver injury group: Patients with Graves' disease without liver injury, showing elevation in AST and/or ALT and/or GGT and/or T-Bil and/or D-Bil levels after ATD treatment, or patients with 40IU/L=ALT=120IU/L in the Graves' disease-related liver injury group, showing further increase in AST and/or ALT and/or GGT and/or T-Bil and/or D-Bil levels after ATD treatment. (3) Willing to use a continuous glucose monitoring system for dynamic blood glucose monitoring. (4) Voluntarily participate and sign an informed consent form before the trial.
Exclusion criteria
Exclusion criteria: (1) Pre-diagnosis of diabetes mellitus (DM) or impaired glucose regulation (IGR), with confirmation of DM based on the results of a 75g oral glucose tolerance test (OGTT) after enrollment. (2) Severe cardiac diseases (chronic heart failure of NYHA class III or IV, acute coronary syndrome, malignant arrhythmias, congenital heart disease, cardiomyopathy, heart valve disease, post-coronary intervention or bypass surgery, post-pacemaker surgery), severe liver disease (Child-Pugh class B or C), severe kidney disease (eGFR 120 IU/L before starting drug therapy, or those with ALT > 200 IU/L after ATD treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glutamic-pyruvic transaminase;Glutamic oxaloacetic transaminase;?- Transpeptidase;Albumin;Direct bilirubin;Indirect bilirubin;Total bilirubin;Thyrotropin;Fee thyroxine;Free triiodothyronine;Thyrotropin receptor antibody;Plasma glucose;C-peptide;Glycosylated hemoglobin;Insulin;Average glucose;Time below range;Time above range;Mean amplitude of glycemic excursions;Coefficient of variance;Standard deviation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Thyriod peroxidase antibody;Antithyroglobulin antibodie;Thyroglobulin;Estimated glycated hemoglobin;Time in range;Height;Weight;Pulse;Systolic pressure;Diastolic pressure; | — |
Countries
China
Contacts
Public ContactDu Jianling
The First Affiliated Hospital of Dalian Medical University
Outcome results
None listed